The Mechanism of Sox4 Transcription in Regulation of Angiogenesis in Hepatocellular Carcinoma (SOX4 in HCC)
SOX4 Activates CXCL12 in Hepatocellular Carcinoma Cells to Modulate Endothelial Cell Migration and Angiogenesis in Vivo
研究概览
详细说明
To determine the role of SOX4 in tumor progression in patients with HCC, we examined SOX4 expression through immunohistochemistry (IHC) staining of 200 formalin-fixed and paraffin-embedded (FFPE) HCC specimens . The SOX4 high group of patients was associated with positive etiology of hepatitis B virus (P = 0.044), tumor size >5 cm (P = 0.014), thrombus formation (P = 0.012), higher microvessel density (MVD) (P = 0.012) in tumor lesions, and distant metastasis (P <0.001).
Cox regression analysis showed that patients with elderly age (P <0.001), higher ⍺-fetal protein (AFP) (P = 0.045), presence of cirrhosis (P = 0.008), and SOX4 high in tumor specimen (P = 0.042) were independent risk factors . The SOX4 high group performed significantly worse regarding overall survival (OS) (P = 0.043) and disease-free survival (DFS) (P = 0.019) based on the Kaplan-Meier analysis.
研究类型
注册 (实际的)
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
描述
Inclusion Criteria:
subjects with pathologic diagnosis of hepatocellular carcinoma and curative partial hepatectomies -
Exclusion Criteria:
history of different malignant disease, subject cannot be treated with curative surgery -
学习计划
研究是如何设计的?
设计细节
队列和干预
团体/队列 |
干预/治疗 |
---|---|
SOX4 high
Nuclear expression of SOX4 over 90% in tumor specimen was defined as SOX4 high group
|
the vessel numbers in high power field with Anti-CD31 staining in tumor specimen
|
SOX4 low
Nuclear expression of SOX4 less than 90% in tumor specimen was defined as SOX4 low group
|
the vessel numbers in high power field with Anti-CD31 staining in tumor specimen
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Disease free survival (DFS)
大体时间:a month
|
The length of time from curative hepatectomies and recurrence or mortality
|
a month
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Overall survival
大体时间:a month
|
The length of time from curative hepatectomies and still alive
|
a month
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- 106-2314-B-182A-113 (其他赠款/资助编号:MOST)
- 103-2314-B-182A-082-MY1-3 (其他赠款/资助编号:MOST)
- CMRPD1G0611 (其他赠款/资助编号:Chang Gung medical foundation)
- CMRPD1H0661 (其他赠款/资助编号:Chang Gung medical foundation)
- CMRPG1J0061 (其他赠款/资助编号:Chang Gung medical foundation)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.